Only in Titles

           Search results for: PARP1 Assay kit    

paperclip

#31773708   // Save this To Up

MicroRNA-577 inhibits cardiomyocyte apoptosis induced by myocardial infarction via targeting PARP1.

The aim of this study was to investigate whether microRNA-577 could inhibit myocardial infarction (MI)-induced cardiomyocyte apoptosis by regulating poly ADP-ribose polymerase 1 (PARP1).

1320 related Products with: MicroRNA-577 inhibits cardiomyocyte apoptosis induced by myocardial infarction via targeting PARP1.

Anti AGO2 Human, Monoclon Anti AGO2 Human, Monoclon Anti AGO2 Mouse, Monoclon Anti AGO2 Mouse, Monoclon Cell Meter™ Caspase 3 7 Annexin V PE Apoptosis De Allergens, Phospholipase Cryo tubes & Vials 4.0 ml Cell Meter™ Annexin V B Annexin V FITC Apoptosis Signal Transduction Anti Cell Meter™ Phosphatidy

Related Pathways

paperclip

#31554189   // Save this To Up

Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells.

Class III receptor tyrosine kinase (RTK) inhibitors targeting mainly FLT3 or c-KIT have not been well studied in lung cancer. To identify a small molecule potentially targeting class III RTK, we synthesized novel small molecule compounds and identified 5-(4-bromophenyl)-N-(naphthalen-1-yl) oxazol-2-amine (AIU2001) as a novel class III RKT inhibitor. In an in vitro kinase profiling assay, AIU2001 inhibited the activities of FLT3, mutated FLT3, FLT4, and c-KIT of class III RTK, and the proliferation of NSCLC cells in vitro and in vivo. AIU2001 induced DNA damage, reactive oxygen species (ROS) generation, and cell cycle arrest in the G2/M phase. Furthermore, AIU2001 suppressed the DNA damage repair genes, resulting in the 'BRCAness'/'DNA-PKness' phenotype. The mRNA expression level of was downregulated by AIU2001 treatment and knockdown of inhibited the DNA repair genes. Our results show that compared to either drug alone, the combination of AIU2001 with a poly (ADP-ribose) polymerase (PARP) inhibitor olaparib or irradiation showed synergistic efficacy in H1299 and A549 cells. Hence, our findings demonstrate that AIU2001 is a candidate therapeutic agent for NSCLC and combination therapies with AIU2001 and a PARP inhibitor or radiotherapy may be used to increase the therapeutic efficacy of AIU2001 due to inhibition of DNA damage repair.

1730 related Products with: Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells.

Lung non small cell cance Non-small cell lung cance Lung small cell carcinoma Middle advanced stage lun Cell Meter™ Fluorimetri Small cell lung carcinoma Oral squamous cell cancer EnzyChrom™ Kinase Assay Non small cell lung carci Multiple lung carcinoma ( MarkerGeneTM Live Dead As Non small cell lung carci

Related Pathways